Practices

Mergers and Acquisitions

Why Cooley

Since 2020, Cooley has handled 1,600+ M&A transactions, with an aggregate value of $735 billion+, making our practice one of the most active in the world.

We represent all categories of participants in transactions, including buyers, sellers, major stockholders, lenders, financial advisors, management, special board committees, venture capitalists, individual investors, private equity funds, hedge funds and others.

>

Recent M&A Experience

Public Company Buy-Side Deals

  • Horizon Therapeutics’ (Nasdaq: HZNP) acquisition of Viela Bio (Nasdaq: VIE) for $3.1 billion
  • Sunrun’s (Nasdaq: RUN) acquisition of Vivint Solar (NYSE: VSLR) in a stock deal valued at $3.2 billion
  • TiVo’s (Nasdaq: TIVO) combination with Xperi (Nasdaq: XPER) for approximately $1.5 billion
  • Eagle Pharmaceutical’s (Nasdaq: EGRX) acquisition of Acacia Pharma (LTS: 0PNT) for $104 million
  • Zoom’s (Nasdaq: ZM) agreement to acquire Five9 (Nasdaq: FIVN) for $14.7 billion

Public Company Sell-Side Deals

  • Horizon Therapeutics’ (Nasdaq: HZNP) sale to Amgen (Nasdaq: AMGN) for $28.3 billion
  • RayzeBio’s (Nasdaq: RYZB) agreement to sell to Bristol Myers Squibb (NYSE: BMY) for approximately $4.1 billion
  • Absolute Software’s (TSE: ABT) sale to Crosspoint Capital for approximately $840 million
  • Gracell Biotechnologies’ (Nasdaq: GRCL) agreement to sell to AstraZeneca (Nasdaq: AZN) for approximately $1.2 billion
  • VectivBio’s (Nasdaq: VECT) sale to Ironwood Pharmaceuticals (Nasdaq: IRWD) for $1 billion cash offer
  • CinCor’s (Nasdaq: CINC) sale to AstraZeneca (LON: AZN) for $1.8 billion
  • Amryt Pharmaceuticals’ (Nasdaq: AMYT) sale to Chiesi Farmaceutici for approximately $1.48 billion
  • Uber’s (NYSE: UBER) sale of 50% Stake in Careem’s Super App to e& for $400 million
  • IAA’s (NYSE: IAA) sale to Ritchie Bros. (NYSE: RBA) in a $7.3 billion stock and cash transaction and IAA’s related cooperation agreement with Ancora Advisors and Ritchie Bros.’ concurrent $500 million investment from Starboard Value
  • ChannelAdvisor’s (NYSE: ECOM) sale to CommerceHub for approximately $664 million

Private Company Buy-Side Deals

  • Merger of equals of Commure and Athelas
  • Zillow’s (Nasdaq: ZG) acquisition of Follow Up Boss for up to $500 million
  • Definitive Healthcare’s (Nasdaq: DHI) acquisition of Populi
  • Tenable’s (Nasdaq: TENB) acquisition of Ermetic
  • Aeglea BioTherapeutics’ acquisition of Spyre Therapeutics
  • ThoughtSpot’s acquisition of Mode Analytics for $200 million
  • Snowflake’s acquisition of Neeva
  • Sprout Social’s acquisition of Tagger Media
  • DigitalOcean’s (NYSE: DOCN) acquisition of Paperspace for $111 million
  • AristaMD’s acquisition of Sitka
  • Cedar Cares’ acquisition of OODA Health for $425 million

Private Company Sell-Side Deals

  • Carmot Therapeutics’s agreement to sell to Roche (SWX: ROG) for up to $3.1 billion
  • Nuvolo’s sale to Trane Technologies (NYSE: TT)
  • Bigfoot Biomedical’s sale to Abbott (NYSE: ABT)
  • Moogsoft’s sale to Dell (NYSE: DELL)
  • M8 Pharmaceuticals’ sale to Acino
  • Propella Therapeutics’ sale to Astellas Pharma (TSE: 4503) for approximately $175 million
  • Happy Money’s agreement to sell to TruStage Ventures
  • MediGO’s sale to CareDx
  • Turning Point Therapeutics’ sale to Bristol Myers Squibb (NYSE: BMY) for $4.1 billion
  • TCGplayer’s sale to eBay for $295 million

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.